Navigation Links
Medical College of Wisconsin study finds drug may limit radiation kidney damage in BMT patients
Date:11/14/2007

Researchers at the Medical College of Wisconsin in Milwaukee have found that the risk of radiation injury in normal tissue after exposure may be reduced by a drug in common use. Their study in press appears in the on line issue of the International Journal of Radiation Oncology, Biology and Physics.

It suggests that long-term administration of the drug captopril, starting at three weeks after patients receive total body irradiation in preparation for bone marrow transplantation (BMT), showed a favorable trend for better long-term kidney function and better long-term patient survival. Chronic kidney failure continues to be a major complication in these patients caused by radiation injury.

The research holds promise, not only for protection of healthy tissue during radiation therapy, but also because it may lead to strategies for protection from radiation injury after nuclear accidents, says Eric P. Cohen, M.D., professor of medicine in the division of nephrology, and principal investigator for the study. Our findings overturned the former dogma that normal tissue radiation injury is untreatable, he says.

Kidney failure is a well known and serious complication of BMT and occurs in up to 50 percent of patients within the first 30 days after transplantation, increasing early mortality. Chronic kidney failure is also common and affects the health and well being of people otherwise cured of the cancer for which the BMT was performed.

In a double-blind placebo-controlled trial, the team tested captopril on 52 adults and three children undergoing bone marrow transplant from July 1998 to January 2006 at Froedtert Hospital and Childrens Hospital of Wisconsin, both major teaching affiliates of the College. When compared to a placebo, captopril-treated subjects had better kidney function and better patient survival.

The statistics do not show a definite significant value, but the trends are there, Dr. Cohen says.

Captopril is an angiotensin-converting enzyme (ACE) inhibitor; a class of drugs that help relax blood vessels, and is currently approved by the U.S. Food and Drug Administration for treatment of hypertension, heart failure, and diabetic nephropathy. Because Captopril may cause leukopenia, the study drug was not started until the new marrow had engrafted in the participants. Leukopenia is a condition in which the white blood cells fall below normal.

The three-week delay in administration of the drug was justified by our animal studies in the late 1990s which showed that a delayed start of captopril could successfully prevent radiation injury to the kidney, Says Dr. Cohen.

In an earlier 1992 animal study, published in Radiation Research, we found that captopril was effective in treating chronic kidney damage and its progression after total body irradiation. That showed that normal tissue radiation injury can be treated, he says.


'/>"/>

Contact: Toranj Marphetia
toranj@mcw.edu
414-456-4744
Medical College of Wisconsin
Source:Eurekalert

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... ... permanently embedded anti-odor solution to cotton knit and woven fabrics. , Retail ... maintaining the luxurious look and feel of cotton. Cotton Incorporated has developed ...
(Date:3/1/2017)... HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... cryoablation for the treatment of early stage breast cancer and where it fits in ... Genes & The Choices We Make .” The event brings together leading cancer and ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living and leading a ... & Go. , Time & Go app is the ultimate strategic compass that helps ... time management methods enable people to work smarter, not harder, that's why Time & ...
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale of ... truth about his life and mysterious disappearance. “McFarnia” is the creation of published author ... North Carolina. He currently serves as a Chaplain with Transport for Christ at a ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Calif. , March 1, 2017   Sun Chlorella ... about all things chlorella, is pleased to announce Non-GMO Project ... premium chlorella powder. Just in time for the ... in Anaheim, CA , Sun Chlorella Corp. ... all chlorella products, including: Sun Chlorella ...
(Date:3/1/2017)... 2017  Integrated Modular Design (IMD), a ... implementation of pre-fabricated healthcare products like bathroom ... seeks to lead the construction industry toward ... Fueled by their leading-edge pre-fabrication solutions, ... construction timelines and project risk, and increasing ...
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
Breaking Medicine Technology: